Nomura Holdings’s Viking Therapeutics VKTX Stock Holding History

Nomura Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$1.06M	–	2144
2025 Q4	$1.06M	Buy	+30,000	New	+$1.06M	﹤0.01%	1318
2024 Q2	–	Sell	-36,000	Closed	-$2.95M	–	2049
2024 Q1	$2.95M	Buy	+36,000	New	+$1.6M	0.01%	788
2023 Q3	–	Sell	-81,500	Closed	-$1.32M	–	1661
2023 Q2	$1.32M	Buy	+81,500	New	+$1.71M	﹤0.01%	823

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Nomura Holdings's VKTX Position: Q1 2026 in Review

Nomura Holdings sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 30,000 shares — an estimated $1.06M sold.

Nomura Holdings first reported a position in VKTX in Q4 2019 and held it in 5 quarters. The position peaked at $1.06M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Nomura Holdings reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Nomura Holdings sold 30,000 Viking Therapeutics shares in Q1 2026, an estimated $1.06M.
Nomura Holdings first reported a position in Viking Therapeutics in Q4 2019 and held it in 5 quarters.
Nomura Holdings's Viking Therapeutics position peaked at $1.06M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.